Table 3.
Prognostic factors analysis of 5-year OS
| Parameter | Univariate
|
Multivariate
|
|
|---|---|---|---|
| P-value | P-value | RR (95% CI) | |
| Age (≤60 years) | 0.001 | <0.001 | 3.256 (1.813–5.846) |
| Increased LDH | 0.014 | 0.169 | 0.670 (0.379–1.185) |
| ECOG scores (<2) | 0.003 | 0.013 | 2.603 (1.225–5.533) |
| GCB | 0.024 | 0.016 | 2.239 (1.165–4.304) |
| HDAC6 high expression | 0.001 | 0.006 | 0.443 (0.249–0.790) |
| Ann Arbor staging | <0.001 | <0.001 | 3.321 (1.849–5.964) |
| R-CHOP | 0.053 | 0.082 | 0.566 (0.298–1.074) |
Abbreviations: HDAC6, histone deacetylase 6; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; GCB, germinal center B-cell-like; CHOP, cyclophosphamide, doxorubicine, vincristine, prednisone; R-CHOP, rituximab plus CHOP; RR, rate ratios.